We had speculated that medical devices giant Smith & Nephew (SN.) might look to reinvigorate sales growth with acquisitions. We have not had long to wait since tipping the shares a month ago. The group has announced the acquisition of Maryland-based Osiris Therapeutics for $19 (14.5p) a share, or $660m in total.
IC TIP:
Buy
at
1,473p
The target company is a specialist in regenerative medicine products, including skin, bone graft and articular cartilage substitutes – an area that Smith & Nephew boss Namal Nawana says will help "immediately accelerate" the larger group’s wound management business.
